

Flexibility of the NSAID binding site in the structure of

Nature Structural Biology

3, 927-933

DOI: [10.1038/nsb1196-927](https://doi.org/10.1038/nsb1196-927)

Citation Report

#	ARTICLE	IF	CITATIONS
1	The cyclooxygenase-2 structure: new drugs for an old target?. <i>Nature Structural Biology</i> , 1996, 3, 897-901.	9.7	32
2	Mechanism of Action of Anti-Inflammatory Drugs. <i>Advances in Experimental Medicine and Biology</i> , 1997, 433, 131-138.	0.8	37
3	The Interaction of Arginine 106 of Human Prostaglandin G/H Synthase-2 with Inhibitors Is Not a Universal Component of Inhibition Mediated by Nonsteroidal Anti-inflammatory Drugs. <i>Molecular Pharmacology</i> , 1997, 52, 829-838.	1.0	83
4	Conversion of Prostaglandin G/H Synthase-1 into an Enzyme Sensitive to PGHS-2-selective Inhibitors by a Double His513→ Arg and Ile523→ Val Mutation. <i>Journal of Biological Chemistry</i> , 1997, 272, 9280-9286.	1.6	107
5	Synthesis of Prostaglandin E2 Ethanolamide from Anandamide by Cyclooxygenase-2. <i>Journal of Biological Chemistry</i> , 1997, 272, 21181-21186.	1.6	360
6	Inhibition of Cyclooxygenase: A Novel Approach to Cancer Prevention. <i>Experimental Biology and Medicine</i> , 1997, 216, 201-210.	1.1	194
7	Selective cyclooxygenase-2 inhibitors: pharmacology, clinical effects and therapeutic potential. <i>Expert Opinion on Investigational Drugs</i> , 1997, 6, 609-614.	1.9	21
8	Differential Allosteric Regulation of Prostaglandin H Synthase 1 and 2 by Arachidonic Acid. <i>Journal of Biological Chemistry</i> , 1997, 272, 12393-12398.	1.6	97
9	Cyclo-Oxygenase Isoenzymes. <i>Drugs</i> , 1997, 53, 563-582.	4.9	163
10	Chapter 21. Selective Cyclooxygenase-2 Inhibitors. <i>Annual Reports in Medicinal Chemistry</i> , 1997, , 211-220.	0.5	67
11	Comparison of Prostaglandin H Synthase Isoform Structures Using Limited Proteolytic Digestion. <i>Archives of Biochemistry and Biophysics</i> , 1997, 344, 150-158.	1.4	9
12	Comparative molecular modeling study of the three-dimensional structures of prostaglandin endoperoxide H2 synthase 1 and 2 (COX-1 and COX-2). <i>Journal of Molecular Graphics and Modelling</i> , 1997, 15, 290-300.	1.3	27
13	The structure of mammalian 15-lipoxygenase reveals similarity to the lipases and the determinants of substrate specificity. <i>Nature Structural Biology</i> , 1997, 4, 1003-1009.	9.7	387
14	A molecular dipstick?. <i>Nature Structural Biology</i> , 1997, 4, 966-968.	9.7	13
16	Mechanism of action of aspirin-like drugs. <i>Seminars in Arthritis and Rheumatism</i> , 1997, 26, 2-10.	1.6	130
17	Effects of nimesulide on constitutive and inducible prostanoid biosynthesis in human beings*. <i>Clinical Pharmacology and Therapeutics</i> , 1998, 63, 672-681.	2.3	47
18	Covalent Modification of Cyclooxygenase-2 (COX-2) by 2-Acetoxyphenyl Alkyl Sulfides, a New Class of Selective COX-2 Inactivators. <i>Journal of Medicinal Chemistry</i> , 1998, 41, 4800-4818.	2.9	115
20	Anti-inflammatory drugs and their mechanism of action. <i>Inflammation Research</i> , 1998, 47, 78-87.	1.6	581

#	ARTICLE	IF	CITATIONS
21	Discovery of a new cyclooxygenase-2 lead compound through 3-D database searching and combinatorial chemistry. <i>Bioorganic and Medicinal Chemistry Letters</i> , 1998, 8, 529-534.	1.0	26
22	Structural basis for selective inhibition of COX-2 by nimesulide. <i>Bioorganic and Medicinal Chemistry</i> , 1998, 6, 2337-2344.	1.4	30
23	Design of selective inhibitors of cyclooxygenase-2 as nonulcerogenic anti-inflammatory agents. <i>Current Opinion in Chemical Biology</i> , 1998, 2, 482-490.	2.8	97
24	Cellular regulation of prostaglandin H synthase catalysis. <i>FEBS Letters</i> , 1998, 430, 154-157.	1.3	46
25	Cyclooxygenase-2 Inhibitors in Tumorigenesis (Part I). <i>Journal of the National Cancer Institute</i> , 1998, 90, 1529-1536.	3.0	530
26	The Dynamics of Prostaglandin H Synthases. <i>Journal of Biological Chemistry</i> , 1998, 273, 5801-5807.	1.6	83
27	Stereochemistry of Oxygenation of Linoleic Acid Catalyzed by Prostaglandin Endoperoxide H Synthase-2. <i>Archives of Biochemistry and Biophysics</i> , 1998, 349, 376-380.	1.4	48
28	Mechanism of Action of Nonsteroidal Anti-inflammatory Drugs. <i>American Journal of Medicine</i> , 1998, 104, 2S-8S.	0.6	503
29	CYCLOOXYGENASES 1 AND 2. <i>Annual Review of Pharmacology and Toxicology</i> , 1998, 38, 97-120.	4.2	2,573
30	Biochemical pharmacology of nonsteroidal anti-inflammatory drugs. <i>Biochemical Pharmacology</i> , 1998, 55, 543-547.	2.0	50
31	Aspirin-like Molecules that Covalently Inactivate Cyclooxygenase-2. <i>Science</i> , 1998, 280, 1268-1270.	6.0	257
32	Cyclooxygenase-2 Induction in Congestive Heart Failure. <i>Circulation</i> , 1998, 98, 95-96.	1.6	57
33	Structural Characterization of Arachidonyl Radicals Formed by Prostaglandin H Synthase-2 and Prostaglandin H Synthase-1 Reconstituted with Manganese Protoporphyrin IX. <i>Journal of Biological Chemistry</i> , 1998, 273, 3888-3894.	1.6	72
34	Comparison of Structural Stabilities of Prostaglandin H Synthase-1 and -2. <i>Journal of Biological Chemistry</i> , 1998, 273, 6801-6811.	1.6	42
35	Subcellular Localization of Prostaglandin Endoperoxide H Synthases-1 and -2 by Immunoelectron Microscopy. <i>Journal of Biological Chemistry</i> , 1998, 273, 9886-9893.	1.6	297
36	Mechanism of action of anti-inflammatory drugs: an overview. , 1998, , 1-17.		10
37	Recent advances: Rheumatology. <i>BMJ: British Medical Journal</i> , 1998, 316, 1810-1812.	2.4	3
38	Effects of nitric oxide and nitric oxide-derived species on prostaglandin endoperoxide synthase and prostaglandin biosynthesis. <i>FASEB Journal</i> , 1999, 13, 1121-1136.	0.2	166

#	ARTICLE	IF	CITATIONS
39	Structure, Function, and Inhibition of Prostaglandin Endoperoxide Synthases. , 1999, , 225-261.		3
40	Comparison of the Peroxidase Reaction Kinetics of Prostaglandin H Synthase-1 and -2. Journal of Biological Chemistry, 1999, 274, 16162-16167.	1.6	56
41	Rapid Kinetics of Tyrosyl Radical Formation and Heme Redox State Changes in Prostaglandin H Synthase-1 and -2. Journal of Biological Chemistry, 1999, 274, 21695-21700.	1.6	50
43	A Mechanistic Study of Self-inactivation of the Peroxidase Activity in Prostaglandin H Synthase-1. Journal of Biological Chemistry, 1999, 274, 9231-9237.	1.6	62
44	COX-2 and Alzheimer's disease: potential roles in inflammation and neurodegeneration. Expert Opinion on Investigational Drugs, 1999, 8, 1521-1536.	1.9	51
45	Molecular model of the interaction between nimesulide and human cyclooxygenase-2. British Journal of Rheumatology, 1999, 38, 14-18.	2.5	30
46	Cloning of Linoleate Diol Synthase Reveals Homology with Prostaglandin H Synthases. Journal of Biological Chemistry, 1999, 274, 28219-28224.	1.6	51
47	Overview of COX-2 in inflammation: from the biology to the clinic. , 1999, , 1-30.		5
48	Gastrointestinal effects of COX-2 inhibitors. Expert Opinion on Investigational Drugs, 1999, 8, 963-971.	1.9	28
49	The Membrane Binding Domains of Prostaglandin Endoperoxide H Synthases 1 and 2. Journal of Biological Chemistry, 1999, 274, 32936-32942.	1.6	73
50	The Role of Arginine 120 of Human Prostaglandin Endoperoxide H Synthase-2 in the Interaction with Fatty Acid Substrates and Inhibitors. Journal of Biological Chemistry, 1999, 274, 17109-17114.	1.6	100
51	The Binding of Arachidonic Acid in the Cyclooxygenase Active Site of Mouse Prostaglandin Endoperoxide Synthase-2 (COX-2). Journal of Biological Chemistry, 1999, 274, 23305-23310.	1.6	113
52	Structure-based design of COX-2 selectivity into flurbiprofen. Bioorganic and Medicinal Chemistry Letters, 1999, 9, 307-312.	1.0	95
53	Structural basis of the dynamic mechanism of ligand binding to cyclooxygenase. Bioorganic and Medicinal Chemistry Letters, 1999, 9, 2779-2784.	1.0	51
54	Crystallization of recombinant cyclo-oxygenase-2. Journal of Crystal Growth, 1999, 196, 350-355.	0.7	5
56	Carbocations in the synthesis of prostaglandins by the cyclooxygenase of pgh synthase? a radical departure!. Protein Science, 1999, 8, 1087-1098.	3.1	10
57	MCSS functionality maps for a flexible protein. Proteins: Structure, Function and Bioinformatics, 1999, 37, 512-529.	1.5	40
58	5 Selective Inhibitors of Cyclooxygenase-2 (COX-2). Progress in Medicinal Chemistry, 1999, 36, 201-234.	4.1	172

#	ARTICLE	IF	CITATIONS
59	Arachidonic Acid Oxygenation by COX-1 and COX-2. Journal of Biological Chemistry, 1999, 274, 22903-22906.	1.6	451
60	Selective cyclooxygenase-2 inhibitors as non-ulcerogenic anti-inflammatory agents. Expert Opinion on Therapeutic Patents, 1999, 9, 831-849.	2.4	26
61	REACTIONS OF PROSTAGLANDIN ENDOPEROXIDE SYNTHASE WITH NITRIC OXIDE AND PEROXYNITRITE*. Drug Metabolism Reviews, 1999, 31, 273-294.	1.5	26
62	Computer Simulation of the Interaction of Non-steroidal Anti-inflammatory Drugs: Indoprofen and NS398 with Cyclooxygenase. Journal of Biomolecular Structure and Dynamics, 1999, 16, 901-915.	2.0	6
63	The cyclooxygenase isoforms: structural insights into the conversion of arachidonic acid to prostaglandins. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 1999, 1441, 278-287.	1.2	125
64	Cyclooxygenase 2 inhibitors: discovery, selectivity and the future. Trends in Pharmacological Sciences, 1999, 20, 465-469.	4.0	185
65	COX-2 inhibitors. Lancet, The, 1999, 353, 307-314.	6.3	1,065
66	The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis. Clinical Therapeutics, 1999, 21, 1688-1702.	1.1	124
67	Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 272-277.	3.3	1,222
68	SELECTIVE CYCLOOXYGENASE-2 INHIBITORS. Rheumatic Disease Clinics of North America, 1999, 25, 359-378.	0.8	41
69	Biosynthesis and Metabolism of Eicosanoids. , 1999, , 255-271.		4
70	Hydroperoxide Dependence and Cooperative Cyclooxygenase Kinetics in Prostaglandin H Synthase-1 and -2. Journal of Biological Chemistry, 1999, 274, 20301-20306.	1.6	72
71	Profile and mechanisms of gastrointestinal and other side effects of nonsteroidal anti-inflammatory drugs (NSAIDs). American Journal of Medicine, 1999, 107, 27-35.	0.6	174
72	The structure of the membrane protein squalene-hopene cyclase at 2.0 Å resolution. Journal of Molecular Biology, 1999, 286, 175-187.	2.0	202
73	Fish macrophages express a cyclo-oxygenase-2 homologue after activation. Biochemical Journal, 1999, 340, 153-159.	1.7	79
74	Simulated (Un)Binding of Arachidonic Acid in the Cyclooxygenase site of Prostaglandin H ₂ Synthase-1. Progress in Reaction Kinetics and Mechanism, 2000, 25, 263-298.	1.1	4
75	New insights into physiological and pathophysiological functions of cyclo-oxygenase-2. Current Opinion in Anaesthesiology, 2000, 13, 585-590.	0.9	9
76	Design and syntheses of methyl 2-methyl-2-[2-(4-benzoyl-5-phenyl-7-halo-2-azabicyclo[4.1.0]hept-3-ene)]acetates: novel inhibitors of cyclooxygenase-2 (COX-2) with analgesic-antiinflammatory activity. Drug Development Research, 2000, 49, 75-84.	1.4	5

#	ARTICLE	IF	CITATIONS
78	Enzyme Mechanisms for Polycyclic Triterpene Formation. <i>Angewandte Chemie - International Edition</i> , 2000, 39, 2812-2833.	7.2	389
79	Design and syntheses of diarylisoxazoles: Novel inhibitors of cyclooxygenase-2 (COX-2) with analgesic-antiinflammatory activity. <i>Drug Development Research</i> , 2000, 51, 273-286.	1.4	56
80	The effects of meloxicam, indomethacin or NS-398 on eicosanoid synthesis by fresh human gastric mucosa. <i>Alimentary Pharmacology and Therapeutics</i> , 2000, 14, 795-799.	1.9	11
81	Non-steroidal anti-inflammatory drugs with different cyclooxygenase inhibitory profiles that prevent aberrant crypt foci formation but vary in acute gastrototoxicity in a rat model. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2000, 15, 1386-1392.	1.4	17
82	Cyclooxygenase mechanisms. <i>Current Opinion in Chemical Biology</i> , 2000, 4, 545-552.	2.8	144
83	A method for including protein flexibility in protein-ligand docking: improving tools for database mining and virtual screening. <i>Journal of Molecular Graphics and Modelling</i> , 2000, 18, 247-257.	1.3	72
84	Structural insights into the stereochemistry of the cyclooxygenase reaction. <i>Nature</i> , 2000, 405, 97-101.	13.7	222
85	Tyrosyl radicals in prostaglandin H synthase-1 and -2. <i>Prostaglandins and Other Lipid Mediators</i> , 2000, 62, 231-254.	1.0	40
86	The pharmacological basis of contemporary pain management. , 2000, 88, 163-185.		76
87	530 ps molecular dynamics simulation of indoprofen and NS398 with COX-1 and COX-2. Study of perturbative changes in the complexes. <i>Computational and Theoretical Chemistry</i> , 2000, 498, 133-148.	1.5	6
88	Automated docking and molecular dynamics simulations of nimesulide in the cyclooxygenase active site of human prostaglandin-endoperoxide synthase-2 (COX-2). <i>Journal of Computer-Aided Molecular Design</i> , 2000, 14, 147-160.	1.3	25
89	Chemometric rationalization of the structural and physicochemical basis for selective cyclooxygenase-2 inhibition: toward more specific ligands. <i>Journal of Computer-Aided Molecular Design</i> , 2000, 14, 277-291.	1.3	18
90	Cyclooxygenases: Structural, Cellular, and Molecular Biology. <i>Annual Review of Biochemistry</i> , 2000, 69, 145-182.	5.0	2,636
93	COX-2-Specific Inhibitors - the Emergence of a New Class of Analgesic and Anti-inflammatory Drugs. <i>Clinical Rheumatology</i> , 2000, 19, 331-343.	1.0	105
94	Outcomes studies of drug induced ulcer complications: do we need them and how should they be done?. <i>BMJ: British Medical Journal</i> , 2000, 321, 291-293.	2.4	17
95	COX-2 inhibitors. <i>Medical Journal of Australia</i> , 2000, 173, 433-436.	0.8	22
96	Biochemically based design of cyclooxygenase-2 (COX-2) inhibitors: Facile conversion of nonsteroidal antiinflammatory drugs to potent and highly selective COX-2 inhibitors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000, 97, 925-930.	3.3	242
97	Spatial Requirements for 15-(R)-Hydroxy-5Z,8Z,11Z,13E-eicosatetraenoic Acid Synthesis within the Cyclooxygenase Active Site of Murine COX-2. <i>Journal of Biological Chemistry</i> , 2000, 275, 6586-6591.	1.6	75

#	ARTICLE	IF	CITATIONS
98	Unresolved Issues in the Role of Cyclooxygenase-2 in Normal Physiologic Processes and Disease. Archives of Internal Medicine, 2000, 160, 913.	4.3	136
99	Prostaglandin H Synthase. Journal of Biological Chemistry, 2000, 275, 27608-27614.	1.6	29
100	Arachidonic Acid and Nonsteroidal Anti-inflammatory Drugs Induce Conformational Changes in the Human Prostaglandin Endoperoxide H2 Synthase-2 (Cyclooxygenase-2). Journal of Biological Chemistry, 2000, 275, 40407-40415.	1.6	20
101	Nonsteroidal Anti-Inflammatory Drugs, Acetaminophen, Cyclooxygenase 2, and Fever. Clinical Infectious Diseases, 2000, 31, S211-S218.	2.9	70
102	Flurbiprofen and Enantiomers in Ophthalmic Solution Tested as Inhibitors of Prostanoid Synthesis in Human Blood. Journal of Ocular Pharmacology and Therapeutics, 2000, 16, 345-352.	0.6	5
103	Physiologic characteristics and clinical importance of the cyclooxygenase isoforms in dogs and cats. Journal of the American Veterinary Medical Association, 2000, 217, 721-729.	0.2	62
104	Oxygenation of the Endocannabinoid, 2-Arachidonylglycerol, to Glycerol Prostaglandins by Cyclooxygenase-2. Journal of Biological Chemistry, 2000, 275, 33744-33749.	1.6	347
105	Re-engineering of Human Urokinase Provides a System for Structure-based Drug Design at High Resolution and Reveals a Novel Structural Subsite. Journal of Biological Chemistry, 2000, 275, 7239-7248.	1.6	55
106	Aspirin and other anti-inflammatory drugs. Thorax, 2000, 55, 3S-9.	2.7	67
107	The Mechanism of Action of Anti-Inflammatory Drugs. , 2000, , 1-23.		10
108	Different Catalytically Competent Arrangements of Arachidonic Acid within the Cyclooxygenase Active Site of Prostaglandin Endoperoxide H Synthase-1 Lead to the Formation of Different Oxygenated Products. Journal of Biological Chemistry, 2000, 275, 8501-8507.	1.6	98
109	Stereospecificity of Hydrogen Abstraction in the Conversion of Arachidonic Acid to 15R-HETE by Aspirin-treated Cyclooxygenase-2. Journal of Biological Chemistry, 2000, 275, 4743-4746.	1.6	68
110	The Formation of Stable Fatty Acid Substrate Complexes in Prostaglandin H2 Synthase-1. Archives of Biochemistry and Biophysics, 2000, 380, 39-45.	1.4	25
111	Distinct Influences of Carboxyl Terminal Segment Structure on Function in the Two Isoforms of Prostaglandin H Synthase. Archives of Biochemistry and Biophysics, 2000, 384, 269-279.	1.4	14
112	Selective Inhibition of Cyclooxygenase-2 by C-Phycocyanin, a Biliprotein from Spirulina platensis. Biochemical and Biophysical Research Communications, 2000, 277, 599-603.	1.0	252
113	The effect of non-steroidal anti-inflammatory drugs on human colorectal cancer cells. European Journal of Cancer, 2000, 36, 664-674.	1.3	242
114	New insight into the structure and function of the alternative oxidase. Biochimica Et Biophysica Acta - Bioenergetics, 2000, 1460, 241-254.	0.5	174
115	Effects of caffeine and paracetamol alone or in combination with acetylsalicylic acid on prostaglandin E2 synthesis in rat microglial cells. Neuropharmacology, 2000, 39, 2205-2213.	2.0	93

#	ARTICLE	IF	CITATIONS
116	The Productive Conformation of Arachidonic Acid Bound to Prostaglandin Synthase. <i>Science</i> , 2000, 289, 1933-1937.	6.0	278
117	Analysis of Binding Affinities for Celecoxib Analogues with COX-1 and COX-2 from Combined Docking and Monte Carlo Simulations and Insight into the COX-2/COX-1 Selectivity. <i>Journal of the American Chemical Society</i> , 2000, 122, 9455-9466.	6.6	135
118	Helical Membrane Protein Folding, Stability, and Evolution. <i>Annual Review of Biochemistry</i> , 2000, 69, 881-922.	5.0	582
119	Tyrosine-385 Is Critical for Acetylation of Cyclooxygenase-2 by Aspirin. <i>Journal of the American Chemical Society</i> , 2000, 122, 6514-6515.	6.6	68
120	Modeling Cyclooxygenase Inhibition. Implication of Active Site Hydration on the Selectivity of Ketoprofen Analogues. <i>Journal of Medicinal Chemistry</i> , 2000, 43, 2280-2284.	2.9	49
121	The "Aspirin" of the New Millennium: Cyclooxygenase-2 Inhibitors. <i>Mayo Clinic Proceedings</i> , 2000, 75, 1027-1038.	1.4	97
122	Nonsteroidal anti-inflammatory drug gastropathy. <i>Gastroenterology</i> , 2000, 119, 521-535.	0.6	313
123	COX-2 Selective Nonsteroidal Anti-Inflammatory Drugs. <i>Drugs</i> , 2000, 59, 1207-1216.	4.9	121
124	Ester and Amide Derivatives of the Nonsteroidal Antiinflammatory Drug, Indomethacin, as Selective Cyclooxygenase-2 Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2000, 43, 2860-2870.	2.9	301
125	Cyclooxygenase-2 inhibitors. <i>Advances in Protein Chemistry</i> , 2001, 56, 115-141.	4.4	5
126	Design and Synthesis of Celecoxib and Rofecoxib Analogues as Selective Cyclooxygenase-2 (COX-2) Inhibitors: Replacement of Sulfonamide and Methylsulfonyl Pharmacophores by an Azido Bioisostere. <i>Journal of Medicinal Chemistry</i> , 2001, 44, 3039-3042.	2.9	207
127	A Benefit-Risk Assessment of Caffeine as an Analgesic Adjuvant. <i>Drug Safety</i> , 2001, 24, 1127-1142.	1.4	67
128	Design and Synthesis of 4,5-Diphenyl-4-isoxazolines: Novel Inhibitors of Cyclooxygenase-2 with Analgesic and Antiinflammatory Activity. <i>Journal of Medicinal Chemistry</i> , 2001, 44, 2921-2927.	2.9	167
129	Tyrosyl radical cofactors. <i>Advances in Protein Chemistry</i> , 2001, 58, 317-385.	4.4	52
130	Cyclooxygenase-2: a major therapeutic advance?. <i>American Journal of Medicine</i> , 2001, 110, S42-S45.	0.6	16
131	GASTROINTESTINAL SAFETY OF COX-2 SPECIFIC INHIBITORS. <i>Gastroenterology Clinics of North America</i> , 2001, 30, 921-936.	1.0	26
132	<i>O</i> -Acetylsalicylhydroxamic Acid, a Novel Acetylating Inhibitor of Prostaglandin H ₂ Synthase: Structural and Functional Characterization of Enzyme-Inhibitor Interactions. <i>Molecular Pharmacology</i> , 2001, 60, 1407-1413.	1.0	30
133	Physiological regulation of cyclooxygenase-2 in the kidney. <i>American Journal of Physiology - Renal Physiology</i> , 2001, 281, F1-F11.	1.3	248

#	ARTICLE	IF	CITATIONS
134	COX-2 inhibitors. Medical Journal of Australia, 2001, 174, 368-369.	0.8	4
135	The Future of Antiinflammatory Therapy. Veterinary Clinics of North America Equine Practice, 2001, 17, 245-262.	0.3	5
136	Selektive Cyclooxygenase-2-Hemmer. Schmerz, 2001, 15, 207-219.	2.7	10
137	Cyclooxygenase inhibitors – current status and future prospects. European Journal of Medicinal Chemistry, 2001, 36, 109-126.	2.6	581
138	COX-2 and cancer: a new approach to an old problem. British Journal of Pharmacology, 2001, 134, 1137-1150.	2.7	106
139	Molecular modeling study of COX-2 inhibition by diarylheterocycles and sulindac sulfide. Computational and Theoretical Chemistry, 2001, 549, 111-121.	1.5	7
140	Cyclooxygenase enzymes: catalysis and inhibition. Current Opinion in Structural Biology, 2001, 11, 752-760.	2.6	179
141	Amino Acid Determinants in Cyclooxygenase-2 Oxygenation of the Endocannabinoid 2-Arachidonylglycerol. Journal of Biological Chemistry, 2001, 276, 30072-30077.	1.6	60
142	Prostaglandin Endoperoxide H Synthase-1. Journal of Biological Chemistry, 2001, 276, 10347-10357.	1.6	118
143	The Basis of Prostaglandin Synthesis in Coral. Journal of Biological Chemistry, 2001, 276, 7033-7040.	1.6	54
144	Structure of Eicosapentaenoic and Linoleic Acids in the Cyclooxygenase Site of Prostaglandin Endoperoxide H Synthase-1. Journal of Biological Chemistry, 2001, 276, 37547-37555.	1.6	112
145	Therapeutic potential of COX-2 inhibitors in arthritis. Expert Opinion on Investigational Drugs, 2001, 10, 1317-1325.	1.9	7
146	Cyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin. New England Journal of Medicine, 2001, 345, 1809-1817.	13.9	1,304
147	The origin of 15R-prostaglandins in the Caribbean coral Plexaura homomalla: Molecular cloning and expression of a novel cyclooxygenase. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 7700-7705.	3.3	64
148	Mutational and X-ray Crystallographic Analysis of the Interaction of Dihomo- β -linolenic Acid with Prostaglandin Endoperoxide H Synthases. Journal of Biological Chemistry, 2001, 276, 10358-10365.	1.6	44
150	Structural Characterization of Arachidonyl Radicals Formed by Aspirin-treated Prostaglandin H Synthase-2. Journal of Biological Chemistry, 2002, 277, 38311-38321.	1.6	21
151	Cyclooxygenase-2 – 10 Years Later. Journal of Pharmacology and Experimental Therapeutics, 2002, 300, 367-375.	1.3	445
152	Cyclooxygenase-3 (COX-3): Filling in the gaps toward a COX continuum?. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 13371-13373.	3.3	252

#	ARTICLE	IF	CITATIONS
153	COX-2-selective inhibitors: clinical relevance in surgical and acute pain. <i>European Journal of Anaesthesiology</i> , 2002, 19, 11-20.	0.7	7
154	Translational medicine: targetting cyclo-oxygenase isozymes to prevent cancer. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2002, 95, 267-273.	0.2	11
155	Cyclooxygenase-2 inhibitors: promise or peril?. <i>Mediators of Inflammation</i> , 2002, 11, 275-286.	1.4	37
156	Control of Prostaglandin Stereochemistry at the 15-Carbon by Cyclooxygenases-1 and -2. <i>Journal of Biological Chemistry</i> , 2002, 277, 478-485.	1.6	70
157	Identification of Novel Cyclooxygenase-2 Selective Inhibitors Using Pharmacophore Models. <i>Journal of Medicinal Chemistry</i> , 2002, 45, 1402-1411.	2.9	191
158	COX-2: A Target for Colon Cancer Prevention. <i>Annual Review of Pharmacology and Toxicology</i> , 2002, 42, 55-80.	4.2	294
159	Selective oxygenation of N-arachidonylglycine by cyclooxygenase-2. <i>Biochemical and Biophysical Research Communications</i> , 2002, 296, 612-617.	1.0	69
160	Fatty acid binding to cyclooxygenases. <i>International Congress Series</i> , 2002, 1233, 283-289.	0.2	1
161	Advances in the field of COX-2 inhibition. <i>Expert Opinion on Therapeutic Patents</i> , 2002, 12, 969-989.	2.4	11
162	The structures of prostaglandin endoperoxide H synthases-1 and -2. <i>Prostaglandins and Other Lipid Mediators</i> , 2002, 68-69, 129-152.	1.0	121
163	Recent developments in cyclooxygenase inhibition. <i>Prostaglandins and Other Lipid Mediators</i> , 2002, 68-69, 153-164.	1.0	26
164	Design of peptides and peptidomimetics as COX-2 selective inhibitors. <i>Computational and Theoretical Chemistry</i> , 2002, 577, 107-120.	1.5	1
165	Synthesis of 4-(alkyl(1,2-diphenyl(3,5-dioxypyrazolidinyl)amino)methyl)sulfonamide pharmacophores for evaluation as selective cyclooxygenase-2 (COX-2) inhibitors. <i>Journal of Heterocyclic Chemistry</i> , 2002, 39, 1309-1314.	1.4	7
166	Design, syntheses, and evaluation of 2,3-diphenylcycloprop-2-en-1-ones and oxime derivatives as potential cyclooxygenase-2 (COX-2) inhibitors with analgesic-antiinflammatory activity. <i>Drug Development Research</i> , 2002, 57, 6-17.	1.4	13
167	Design, syntheses, and evaluation of novel 1,1-dihalo-2,3-diphenylcyclopropanes as potential cyclooxygenase-2 (COX-2) inhibitors with analgesic-antiinflammatory activity. <i>Drug Development Research</i> , 2002, 55, 79-90.	1.4	2
168	COX-2 inhibitors for endodontic pain. <i>Endodontic Topics</i> , 2002, 3, 31-40.	0.5	10
169	Structure-Based Design of Cyclooxygenase-2 Selectivity into Ketoprofen. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2002, 12, 533-537.	1.0	59
170	Synthesis and Biological Testing of Acyl-CoA-Ketoprofen Conjugates as Selective Irreversible Inhibitors of COX-2. <i>Bioorganic and Medicinal Chemistry</i> , 2002, 10, 753-757.	1.4	9

#	ARTICLE	IF	CITATIONS
171	Differential binding mode of diverse cyclooxygenase inhibitors. <i>Journal of Molecular Graphics and Modelling</i> , 2002, 20, 359-371.	1.3	75
172	The Effects of Cyclooxygenase Isozyme Inhibition on Incisional Wound Healing in Mouse Skin. <i>Journal of Investigative Dermatology</i> , 2002, 119, 1189-1195.	0.3	61
173	Thiol-modifying inhibitors for understanding squalene cyclase function. <i>FEBS Journal</i> , 2002, 269, 2108-2116.	0.2	15
174	Copper complexes of non-steroidal anti-inflammatory drugs: an opportunity yet to be realized. <i>Coordination Chemistry Reviews</i> , 2002, 232, 95-126.	9.5	469
175	Molecular modelling of the differential interaction between several non-steroidal anti-inflammatory drugs and human prostaglandin endoperoxide H synthase-2 (h-PGHS-2). <i>Journal of Molecular Graphics and Modelling</i> , 2002, 20, 329-343.	1.3	34
176	Synthesis of Isotopically Labeled Arachidonic Acids To Probe the Reaction Mechanism of Prostaglandin H Synthase. <i>Journal of the American Chemical Society</i> , 2002, 124, 10785-10796.	6.6	46
177	Requirement of cyclooxygenase-2 expression and prostaglandins for human prostate cancer cell invasion. <i>Clinical and Experimental Metastasis</i> , 2002, 19, 593-601.	1.7	67
178	Osteoarthritis IV: Clinical therapeutic trials and treatment. <i>Inflammopharmacology</i> , 2002, 10, 79-155.	1.9	24
179	Absence of nuclear factor κ B inhibition by NSAIDs in hepatocytes. <i>Hepatology</i> , 2002, 35, 341-348.	3.6	21
180	The enzymology of prostaglandin endoperoxide H synthases-1 and -2. <i>Prostaglandins and Other Lipid Mediators</i> , 2002, 68-69, 115-128.	1.0	143
181	Crossreacting Drugs and Chemicals. <i>Clinical Reviews in Allergy and Immunology</i> , 2003, 24, 149-158.	2.9	17
182	The Structure of Mammalian Cyclooxygenases. <i>Annual Review of Biophysics and Biomolecular Structure</i> , 2003, 32, 183-206.	18.3	119
183	Cyclooxygenase-2 Inhibitors. <i>Anesthesia and Analgesia</i> , 2003, 96, 1720-1738.	1.1	69
184	Cyclooxygenase-2 inhibitor treatment of older osteoarthritis patients. <i>Comprehensive Therapy</i> , 2003, 29, 215-223.	0.2	1
186	The role of prostaglandins in the initiation of parturition. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2003, 17, 717-730.	1.4	212
187	Selective Cyclooxygenase-2 Inhibition: A Target in Cancer Prevention and Treatment. <i>Pharmacotherapy</i> , 2003, 23, 9-28.	1.2	45
188	Design and synthesis of novel celecoxib analogues as selective cyclooxygenase-2 (COX-2) inhibitors: replacement of the sulfonamide pharmacophore by a sulfonylazide bioisostere. <i>Bioorganic and Medicinal Chemistry</i> , 2003, 11, 5273-5280.	1.4	50
189	Ab initio structure determination of rofecoxib from powder diffraction data using molecular packing analysis method and direct space method. <i>International Journal of Pharmaceutics</i> , 2003, 252, 213-223.	2.6	7

#	ARTICLE	IF	CITATIONS
190	Conformationally restricted 3,4-diarylfuranones (2,3a,4,5-tetrahydronaphthofuranones) as selective cyclooxygenase-2 inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2003, 13, 1639-1643.	1.0	48
191	6-Alkyl, alkoxy, or alkylthio-substituted 3-(4-methanesulfonylphenyl)-4-phenylpyran-2-ones: a novel class of diarylheterocyclic selective cyclooxygenase-2 inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2003, 13, 2205-2209.	1.0	42
192	The development of COX2 inhibitors. <i>Nature Reviews Drug Discovery</i> , 2003, 2, 179-191.	21.5	390
193	COX-2 and beyond: approaches to prostaglandin inhibition in human disease. <i>Nature Reviews Drug Discovery</i> , 2003, 2, 879-890.	21.5	439
194	Dual inhibition of cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) as a new strategy to provide safer non-steroidal anti-inflammatory drugs. <i>European Journal of Medicinal Chemistry</i> , 2003, 38, 645-659.	2.6	374
195	Antiinflammatory Property of 3-Aryl-5-(n-propyl)-1,2,4-oxadiazoles and Antimicrobial Property of 3-Aryl-5-(n-propyl)-4,5-dihydro-1,2,4-oxadiazoles: Their Syntheses and Spectroscopic Studies. <i>Bioorganic and Medicinal Chemistry</i> , 2003, 11, 1821-1827.	1.4	66
196	Computer-aided design of non sulphonyl COX-2 inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2003, 11, 3989-3996.	1.4	18
197	Cyclooxygenase (COX) Inhibitors: A Comparative QSAR Study. <i>Chemical Reviews</i> , 2003, 103, 703-732.	23.0	72
198	Quantum Chemical Studies of Radical-Containing Enzymes. <i>Chemical Reviews</i> , 2003, 103, 2421-2456.	23.0	266
199	A Novel Mechanism of Cyclooxygenase-2 Inhibition Involving Interactions with Ser-530 and Tyr-385. <i>Journal of Biological Chemistry</i> , 2003, 278, 45763-45769.	1.6	257
200	A Quantum Chemical Study of the Synthesis of Prostaglandin G2 by the Cyclooxygenase Active Site in Prostaglandin Endoperoxide H Synthase 1. <i>Journal of Physical Chemistry B</i> , 2003, 107, 3297-3308.	1.2	27
201	Synthesis and Cyclooxygenase-2 Inhibiting Property of 1,5-Diarylpyrazoles with Substituted Benzenesulfonamide Moiety as Pharmacophore: A Preparation of Sodium Salt for Injectable Formulation. <i>Journal of Medicinal Chemistry</i> , 2003, 46, 3975-3984.	2.9	44
202	Cyclooxygenase 2 (COX-2) as a target for therapy and noninvasive imaging. <i>Molecular Imaging and Biology</i> , 2003, 5, 286-303.	1.3	33
203	Functional analysis of the molecular determinants of cyclooxygenase-2 acetylation by 2-acetoxyphenylhept-2-ynyl sulfide. <i>Archives of Biochemistry and Biophysics</i> , 2003, 409, 127-133.	1.4	8
204	Comparison of the properties of prostaglandin H synthase-1 and -2. <i>Progress in Lipid Research</i> , 2003, 42, 377-404.	5.3	80
205	Mechanism of Free Radical Oxygenation of Polyunsaturated Fatty Acids by Cyclooxygenases. <i>Chemical Reviews</i> , 2003, 103, 2239-2304.	23.0	229
206	Clinical pharmacology of etoricoxib: a novel selective COX2 inhibitor. <i>Expert Opinion on Pharmacotherapy</i> , 2003, 4, 265-284.	0.9	44
207	Membrane Protein Crystallization. , 2003, , 143-160.		10

#	ARTICLE	IF	CITATIONS
208	A Novel Family of Hydroxamate-Based Acylating Inhibitors of Cyclooxygenase. <i>Molecular Pharmacology</i> , 2003, 63, 450-455.	1.0	31
209	Clinical evaluation of a nutraceutical, carprofen and meloxicam for the treatment of dogs with osteoarthritis. <i>Veterinary Record</i> , 2003, 152, 323-329.	0.2	157
210	Histidine 386 and Its Role in Cyclooxygenase and Peroxidase Catalysis by Prostaglandin-endoperoxide H Synthases. <i>Journal of Biological Chemistry</i> , 2003, 278, 46163-46170.	1.6	13
211	Nitrous Oxide Attenuates Pressor but Augments Norepinephrine Response to Laryngoscopy and Endotracheal Intubation. <i>Anesthesia and Analgesia</i> , 2003, 96, 1516-1521.	1.1	5
212	An Evaluation of the Dose-Dependent Inhibition of CYP1A2 by Rofecoxib Using Theophylline as a CYP1A2 Probe. <i>Journal of Clinical Pharmacology</i> , 2003, 43, 1082-1090.	1.0	21
213	Pharmacology of COX-2 Inhibitors. , 2003, 37, 25-51.		5
214	Cyclooxygenase Enzymes: Regulation and Function. <i>Current Pharmaceutical Design</i> , 2004, 10, 577-588.	0.9	256
215	Clinical Pharmacology of Novel Selective COX-2 Inhibitors. <i>Current Pharmaceutical Design</i> , 2004, 10, 589-601.	0.9	62
216	Oxidative Metabolism of Endocannabinoids by COX-2. <i>Current Pharmaceutical Design</i> , 2004, 10, 659-667.	0.9	134
217	Crystal Structure of Arachidonic Acid Bound to a Mutant of Prostaglandin Endoperoxide H Synthase-1 That Forms Predominantly 11-Hydroperoxyeicosatetraenoic Acid. <i>Journal of Biological Chemistry</i> , 2004, 279, 42929-42935.	1.6	24
218	On the Evolutionary Origin of Cyclooxygenase (COX) Isozymes. <i>Journal of Biological Chemistry</i> , 2004, 279, 13624-13633.	1.6	54
219	Characterization of the Heme Environment in Arabidopsis thaliana Fatty Acid $\hat{1}\pm$ -Dioxygenase-1. <i>Journal of Biological Chemistry</i> , 2004, 279, 29805-29815.	1.6	20
220	Cyclooxygenase-1-dependent Prostaglandin Synthesis Modulates Tumor Necrosis Factor- $\hat{1}\pm$ Secretion in Lipopolysaccharide-challenged Murine Resident Peritoneal Macrophages. <i>Journal of Biological Chemistry</i> , 2004, 279, 34256-34268.	1.6	41
221	The molecular and biological basis for COX-2 selectivity. , 2004, , 41-65.		0
222	Structural diversity of selective COX-2 inhibitors. , 2004, , 15-40.		5
223	ABT-963 [2-(3,4-Difluoro-phenyl)-4-(3-hydroxy-3-methyl-butoxy)-5-(4-methanesulfonyl-phenyl)-2H-pyridazin-3-one], A Highly Potent and Selective Disubstituted Pyridazinone Cyclooxygenase-2 Inhibitor. <i>Journal of Pharmacology and Experimental Therapeutics</i> . 2004. 311. 904-912.	1.3	40
224	Leukotriene A4 Hydrolase. <i>Journal of Biological Chemistry</i> , 2004, 279, 27376-27382.	1.6	46
225	Cyclooxygenase Isozymes: The Biology of Prostaglandin Synthesis and Inhibition. <i>Pharmacological Reviews</i> , 2004, 56, 387-437.	7.1	1,427

#	ARTICLE	IF	CITATIONS
227	Prognostic Impact of Cyclooxygenase-2 in Breast Cancer. <i>Clinical Breast Cancer</i> , 2004, 4, 428-433.	1.1	68
228	Computational studies and peptidomimetic design for the human p53-MDM2 complex. <i>Proteins: Structure, Function and Bioinformatics</i> , 2004, 58, 222-234.	1.5	78
229	Synergistic inhibitory effect of ascorbic acid and acetylsalicylic acid on prostaglandin E2 release in primary rat microglia. <i>Journal of Neurochemistry</i> , 2004, 86, 173-178.	2.1	38
230	Cyclooxygenase and 5-lipoxygenase pathways in the vessel wall: Role in atherosclerosis. <i>Medicinal Research Reviews</i> , 2004, 24, 399-424.	5.0	94
231	Design and synthesis of acyclic triaryl (Z)-olefins: a novel class of cyclooxygenase-2 (COX-2) inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2004, 12, 5929-5940.	1.4	60
232	Theoretical study on the structure and reactive sites of non-steroidal anti-inflammatory drugs. <i>Computational and Theoretical Chemistry</i> , 2004, 682, 55-62.	1.5	31
233	Sulfonamido, azidosulfonyl and N-acetylsulfonamido analogues of rofecoxib: 4-[4-(N-acetylsulfonamido)phenyl]-3-(4-methanesulfonylphenyl)-2(5H)furanone is a potent and selective cyclooxygenase-2 inhibitor. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2004, 14, 1957-1960.	1.0	17
234	Rational design of 6-methylsulfonylindoles as selective cyclooxygenase-2 inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2004, 14, 4741-4745.	1.0	50
235	Receptor Flexibility in the in Silico Screening of Reagents in the S1â€ Pocket of Human Collagenase. <i>Journal of Medicinal Chemistry</i> , 2004, 47, 2761-2767.	2.9	25
236	Selective cyclooxygenaseâ€2 inhibitors: similarities and differences. <i>Scandinavian Journal of Rheumatology</i> , 2004, 33, 1-6.	0.6	124
237	The cyclooxygenases. <i>Genome Biology</i> , 2004, 5, 241.	13.9	222
238	Cyclooxygenases in cancer: progress and perspective. <i>Cancer Letters</i> , 2004, 215, 1-20.	3.2	368
239	Prostaglandin endoperoxide H synthase inhibitors and other tocolytics in preterm labour. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2004, 70, 167-187.	1.0	17
240	A Free Energy Based Computational Pathway from Chemical Templates to Lead Compounds: A Case Study of COX-2 Inhibitors. <i>Journal of Biomolecular Structure and Dynamics</i> , 2004, 21, 791-804.	2.0	7
241	Recent advances in molecular biology and physiology of the prostaglandin E2-biosynthetic pathway. <i>Progress in Lipid Research</i> , 2004, 43, 3-35.	5.3	314
242	Detergents profoundly affect inhibitor potencies against both cyclo-oxygenase isoforms. <i>Biochemical Journal</i> , 2004, 377, 675-684.	1.7	24
243	Oxygenation by COX-2 (cyclo-oxygenase-2) of 3-HETE (3-hydroxyeicosatetraenoic acid), a fungal mimetic of arachidonic acid, produces a cascade of novel bioactive 3-hydroxyeicosanoids. <i>Biochemical Journal</i> , 2005, 390, 737-747.	1.7	31
244	Similarities among receptor pockets and among compounds: Analysis and application to in silico ligand screening. <i>Journal of Molecular Graphics and Modelling</i> , 2005, 24, 34-45.	1.3	87

#	ARTICLE	IF	CITATIONS
245	An overview of the recent developments in analytical methodologies for determination of COX-2 inhibitors in bulk drugs, pharmaceuticals and biological matrices. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2005, 39, 349-363.	1.4	52
246	Design and synthesis of (E)-1,1,2-triarylethenes: novel inhibitors of the cyclooxygenase-2 (COX-2) isozyme. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2005, 15, 439-442.	1.0	19
247	A new potential cyclooxygenase-2 inhibitor, pyridinic analogue of nimesulide. <i>European Journal of Medicinal Chemistry</i> , 2005, 40, 1316-1324.	2.6	23
248	Vibrational and theoretical studies of the non-steroidal anti-inflammatory drugs Niflumic [2-3((3-trifluoromethyl)phenylamino)-3-pyridinecarboxylic acid]; Diclofenac [[2-(2,6-dichlorophenyl)amino]-benzeneacetic acid] and Indometacin acids [1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-acetic acid]. <i>Vibrational Spectroscopy</i> , 2005, 37, 161-178.	1.2	21
249	The Role of COX-2 in Acute Pain and the Use of Selective COX-2 Inhibitors for Acute Pain Relief. <i>Current Pharmaceutical Design</i> , 2005, 11, 1737-1755.	0.9	60
250	Pharmacological properties of nimesulide. , 2005, , 133-244.		4
251	RAW264.7 cells lack prostaglandin-dependent autoregulation of tumor necrosis factor- α secretion. <i>Journal of Lipid Research</i> , 2005, 46, 1027-1037.	2.0	37
253	Non-steroidal anti-inflammatory drugs. , 2005, , 499-510.		0
254	Glycerolprostaglandin Synthesis by Resident Peritoneal Macrophages in Response to a Zymosan Stimulus. <i>Journal of Biological Chemistry</i> , 2005, 280, 26690-26700.	1.6	49
255	Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. <i>Journal of Clinical Investigation</i> , 2005, 116, 4-15.	3.9	851
256	Late complications of an ileal pouch. <i>Gut</i> , 2005, 54, 1514-1514.	6.1	0
257	Optimization and Validation of a Docking-Scoring Protocol; Application to Virtual Screening for COX-2 Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 1055-1068.	2.9	43
258	COX-2: A Molecular Target for Colorectal Cancer Prevention. <i>Journal of Clinical Oncology</i> , 2005, 23, 2840-2855.	0.8	497
259	COX-2 chronology. <i>Gut</i> , 2005, 54, 1509-1514.	6.1	35
260	Stereoselective Binding of Indomethacin Ethanolamide Derivatives to Cyclooxygenase-1. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 3613-3620.	2.9	34
261	Expanding the ChemGPS Chemical Space with Natural Products. <i>Journal of Natural Products</i> , 2005, 68, 985-991.	1.5	75
262	Structural and functional differences between cyclooxygenases: Fatty acid oxygenases with a critical role in cell signaling. <i>Biochemical and Biophysical Research Communications</i> , 2005, 338, 34-44.	1.0	48
263	Regulation of cyclooxygenase catalysis by hydroperoxides. <i>Biochemical and Biophysical Research Communications</i> , 2005, 338, 25-33.	1.0	44

#	ARTICLE	IF	CITATIONS
264	New insights into COX-2 biology and inhibition. <i>Brain Research Reviews</i> , 2005, 48, 352-359.	9.1	105
265	cDNA cloning and expression analysis of a cyclooxygenase-2 from sea bass (<i>Dicentrarchus labrax</i> L.) after vaccination. <i>Aquaculture</i> , 2005, 245, 301-310.	1.7	10
266	The use of NSAIDs in rheumatic disorders 2005: a global perspective. <i>Inflammopharmacology</i> , 2005, 13, 343-370.	1.9	110
267	Structural Bioinformatics in Drug Discovery. <i>Methods of Biochemical Analysis</i> , 2005, 44, 477-497.	0.2	9
269	A Computational Protocol for the Integration of the Monotopic Protein Prostaglandin H2 Synthase into a Phospholipid Bilayer. <i>Biophysical Journal</i> , 2006, 91, 401-410.	0.2	21
270	Molecular Dynamics Simulations of Arachidonic Acid Complexes with COX-1 and COX-2: Insights into Equilibrium Behavior. <i>Biochemistry</i> , 2006, 45, 3189-3205.	1.2	44
271	Synthesis and Structure-Activity Relationship Studies of 1,3-Diarylprop-2-yn-1-ones: Dual Inhibitors of Cyclooxygenases and Lipoxygenases. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 1668-1683.	2.9	76
272	Role of Tyr348 in Tyr385 Radical Dynamics and Cyclooxygenase Inhibitor Interactions in Prostaglandin H Synthase-2. <i>Biochemistry</i> , 2006, 45, 523-532.	1.2	25
273	Classification of Chemical Compounds by Protein-Compound Docking for Use in Designing a Focused Library. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 523-533.	2.9	42
274	Prostaglandin E2 synthesis and secretion: The role of PGE2 synthases. <i>Clinical Immunology</i> , 2006, 119, 229-240.	1.4	586
275	Experimental study of the action of COX-2 selective nonsteroidal anti-inflammatory drugs and traditional anti-inflammatory drugs in bone regeneration. <i>Clinics</i> , 2006, 61, 223-230.	0.6	12
277	Zymosan-induced glycerylprostaglandin and prostaglandin synthesis in resident peritoneal macrophages: roles of cyclo-oxygenase-1 and -2. <i>Biochemical Journal</i> , 2006, 399, 91-99.	1.7	26
280	Cyclooxygenase-2 as a target for anticancer drug development. <i>Critical Reviews in Oncology/Hematology</i> , 2006, 59, 51-64.	2.0	186
281	Structure-based pharmacophore of COX-2 selective inhibitors and identification of original lead compounds from 3D database searching method. <i>European Journal of Medicinal Chemistry</i> , 2006, 41, 1446-1455.	2.6	35
282	Design, synthesis, and biological evaluation of (E)-3-(4-methanesulfonylphenyl)-2-(aryl)acrylic acids as dual inhibitors of cyclooxygenases and lipoxygenases. <i>Bioorganic and Medicinal Chemistry</i> , 2006, 14, 7716-7727.	1.4	33
283	Cyclooxygenase: Past, present and future. A tribute to John R. Vane (1927-2004). <i>Journal of Thermal Biology</i> , 2006, 31, 208-219.	1.1	71
284	Ascorbic acid enhances the inhibitory effect of aspirin on neuronal cyclooxygenase-2-mediated prostaglandin E2 production. <i>Journal of Neuroimmunology</i> , 2006, 174, 39-51.	1.1	41
285	Contributions of cyclooxygenase-2 to neuroplasticity and neuropathology of the central nervous system. , 2006, 112, 335-357.		77

#	ARTICLE	IF	CITATIONS
286	Oxidative alterations of cyclooxygenase during atherogenesis. Prostaglandins and Other Lipid Mediators, 2006, 80, 1-14.	1.0	35
287	Antipyretic Analgesics: Nonsteroidal Antiinflammatory Drugs, Selective COX-2 Inhibitors, Paracetamol and Pyrazolinones. , 2007, , 65-93.		36
288	Implications of the Molecular Basis of Prostacyclin Biosynthesis and Signaling in Pharmaceutical Designs. Current Pharmaceutical Design, 2006, 12, 925-941.	0.9	16
289	Topography of the Prostaglandin Endoperoxide H2 Synthase-2 in Membranes. Journal of Biological Chemistry, 2006, 281, 28354-28364.	1.6	20
290	Prostaglandin Endoperoxide H Synthases. Journal of Biological Chemistry, 2007, 282, 18233-18244.	1.6	37
291	Unique Peroxidase Reaction Mechanism in Prostaglandin Endoperoxide H Synthase-2. Journal of Biological Chemistry, 2007, 282, 16681-16690.	1.6	8
292	Current and Future Clinical Strategies in Colon Cancer Prevention and the Emerging Role of Chemoprevention. Current Pharmaceutical Design, 2007, 13, 2274-2282.	0.9	52
293	Computer Aided Drug Design Approaches to Develop Cyclooxygenase Based Novel Anti-Inflammatory and Anti-Cancer Drugs. Current Pharmaceutical Design, 2007, 13, 3505-3517.	0.9	40
294	A Tale of Switched Functions: From Cyclooxygenase Inhibition to M-Channel Modulation in New Diphenylamine Derivatives. PLoS ONE, 2007, 2, e1332.	1.1	34
295	Structural Basis of Enantioselective Inhibition of Cyclooxygenase-1 by S- $\hat{\pm}$ -Substituted Indomethacin Ethanolamides. Journal of Biological Chemistry, 2007, 282, 28096-28105.	1.6	87
296	Prostaglandin signaling and ovarian follicle development in the silkworm, Bombyx mori. Insect Biochemistry and Molecular Biology, 2007, 37, 876-885.	1.2	63
297	Structural and Functional Basis of Cyclooxygenase Inhibition. Journal of Medicinal Chemistry, 2007, 50, 1425-1441.	2.9	420
298	A Critical Role of Non-active Site Residues on Cyclooxygenase Helices 5 and 6 in the Control of Prostaglandin Stereochemistry at Carbon 15. Journal of Biological Chemistry, 2007, 282, 28157-28163.	1.6	3
299	Perspective Assessment of COX-1 and COX-2 Selectivity of Nonsteroidal Anti-Inflammatory Drugs from Clinical Practice: Use of Genetic Function Approximation. Journal of Chemical Information and Modeling, 2007, 47, 635-643.	2.5	10
300	Drug Insight: cyclo-oxygenase-2 inhibitors—a critical appraisal. Nature Clinical Practice Rheumatology, 2007, 3, 552-560.	3.2	46
301	Structure-Based Design, Synthesis, and Biological Evaluation of Indomethacin Derivatives as Cyclooxygenase-2 Inhibiting Nitric Oxide Donors. Journal of Medicinal Chemistry, 2007, 50, 6367-6382.	2.9	52
302	Cyclooxygenase-2 as target for chemopreventive interventions: New approaches. Cancer Biomarkers, 2007, 3, 153-161.	0.8	7
303	The Multiple Pathways of Endocannabinoid Metabolism: A Zoom Out. Chemistry and Biodiversity, 2007, 4, 1858-1881.	1.0	35

#	ARTICLE	IF	CITATIONS
304	Studies on 1,2,4-triazole Derivatives as Potential Anti-inflammatory Agents. <i>Archiv Der Pharmazie</i> , 2007, 340, 586-590.	2.1	50
305	Synthesis and biological evaluation of methanesulfonamide analogues of rofecoxib: Replacement of methanesulfonyl by methanesulfonamido decreases cyclooxygenase-2 selectivity. <i>Bioorganic and Medicinal Chemistry</i> , 2007, 15, 1056-1061.	1.4	44
306	Non-carboxylic analogues of arylpropionic acids: Synthesis, anti-inflammatory activity and ulcerogenic potential. <i>European Journal of Medicinal Chemistry</i> , 2007, 42, 152-160.	2.6	34
307	Control of Oxygenation in Lipoxygenase and Cyclooxygenase Catalysis. <i>Chemistry and Biology</i> , 2007, 14, 473-488.	6.2	265
308	COX-1 und COX-2: Funktionen und pharmakologische Beeinflussung. <i>Pharmazie in Unserer Zeit</i> , 1999, 28, 21-29.	0.0	6
309	Design, synthesis and pharmacological evaluation of 4-[2-alkylthio-5(4)-(4-substitutedphenyl)imidazole-4(5)yl]benzenesulfonamides as selective COX-2 inhibitors. <i>Acta Pharmacologica Sinica</i> , 2007, 28, 1254-1260.	2.8	9
310	Reprint of "Oxidative alterations of cyclooxygenase during atherogenesis" [Prostag. Oth. Lipid. M. 80 (2006) 1-14]. <i>Prostaglandins and Other Lipid Mediators</i> , 2007, 82, I-XIV.	1.0	2
311	Novel anti-inflammatory agents based on pyridazinone scaffold; design, synthesis and in vivo activity. <i>Bioorganic and Medicinal Chemistry</i> , 2008, 16, 5547-5556.	1.4	52
312	Synthesis and evaluation in vitro and in vivo of a 11C-labeled cyclooxygenase-2 (COX-2) inhibitor. <i>Bioorganic and Medicinal Chemistry</i> , 2008, 16, 7662-7670.	1.4	47
313	Computer-Aided Discovery of Anti-Inflammatory Thiazolidinones with Dual Cyclooxygenase/Lipoxygenase Inhibition. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 1601-1609.	2.9	161
314	Photo-crosslinking of proteins in intact cells reveals a dimeric structure of cyclooxygenase-2 and an inhibitor-sensitive oligomeric structure of microsomal prostaglandin E2 synthase-1. <i>Archives of Biochemistry and Biophysics</i> , 2008, 477, 155-162.	1.4	9
315	Management of chronic musculoskeletal pain in the Elderly: Opinions on oral medication use. <i>Inflammopharmacology</i> , 2008, 16, 53-75.	1.9	55
316	Oxidative Metabolism of a Fatty Acid Amide Hydrolase-Regulated Lipid, Arachidonoyltaurine. <i>Biochemistry</i> , 2008, 47, 3917-3925.	1.2	22
317	Cannabidiolic Acid as a Selective Cyclooxygenase-2 Inhibitory Component in Cannabis. <i>Drug Metabolism and Disposition</i> , 2008, 36, 1917-1921.	1.7	105
318	Non-redundant Functions of Cyclooxygenases: Oxygenation of Endocannabinoids. <i>Journal of Biological Chemistry</i> , 2008, 283, 8065-8069.	1.6	100
319	Effect of a nonprotein bioactive agent on the reduction of cyclooxygenase-2 and tumor necrosis factor- α in human intervertebral disc cells in vitro. <i>Journal of Neurosurgery: Spine</i> , 2008, 9, 411-418.	0.9	10
320	Evolution of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Cyclooxygenase (COX) Inhibition and Beyond. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2008, 11, 81.	0.9	525
321	Cyclooxygenase as a target for chemoprevention in colorectal cancer: lost cause or a concept coming of age?. <i>Expert Opinion on Therapeutic Targets</i> , 2009, 13, 209-218.	1.5	20

#	ARTICLE	IF	CITATIONS
322	Prodrug Designing of NSAIDs. Mini-Reviews in Medicinal Chemistry, 2009, 9, 124-139.	1.1	52
323	Antiinflammatory and antinociceptive activities of gossypin and procumbentin " cyclooxygenase" (COX) inhibition studies. Phytotherapy Research, 2009, 23, 878-884.	2.8	22
324	Peroxide-induced radical formation at TYR385 and TYR504 in human PGHS-1. Journal of Inorganic Biochemistry, 2009, 103, 912-922.	1.5	10
325	Dinitroglyceryl and diazen-1-ium-1,2-diolated nitric oxide donor ester prodrugs of aspirin, indomethacin and ibuprofen: Synthesis, biological evaluation and nitric oxide release studies. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 3014-3018.	1.0	35
326	Characterization of an AM404 Analogue, <i>N</i> -(3-Hydroxyphenyl)arachidonoylamide, as a Substrate and Inactivator of Prostaglandin Endoperoxide Synthase. Biochemistry, 2009, 48, 12233-12241.	1.2	4
327	Inhibition of arachidonic acid metabolism and its implication on cell proliferation and tumour-angiogenesis. International Immunopharmacology, 2009, 9, 701-715.	1.7	134
328	In Silico Fragment Screening by Replica Generation (FSRG) Method for Fragment-Based Drug Design. Journal of Chemical Information and Modeling, 2009, 49, 925-933.	2.5	18
329	Rofecoxib: an update on physicochemical, pharmaceutical, pharmacodynamic and pharmacokinetic aspects. Journal of Pharmacy and Pharmacology, 2010, 55, 859-894.	1.2	29
330	Synthesis, anti-inflammatory evaluation and docking studies of some new fluorinated fused quinazolines. European Journal of Medicinal Chemistry, 2010, 45, 4904-4913.	2.6	159
331	Modeling the binding modes of stilbene analogs to cyclooxygenase-2: a molecular docking study. Journal of Molecular Modeling, 2010, 16, 1919-1929.	0.8	27
332	Molecular simulation study of the binding mechanism of [±-PTi2W10O40]7- for its promising broad-spectrum inhibitory activity to FluV-A neuraminidase. Science Bulletin, 2010, 55, 2497-2504.	1.7	2
333	Nonsteroidal Anti-Inflammatory Drugs: Adverse Effects and Their Prevention. Seminars in Arthritis and Rheumatism, 2010, 39, 294-312.	1.6	245
334	Design, synthesis, and biological evaluation of ketoprofen analogs as potent cyclooxygenase-2 inhibitors. Bioorganic and Medicinal Chemistry, 2010, 18, 5855-5860.	1.4	57
335	Non-Steroidal Anti-Inflammatory Drugs: An Overview of Cardiovascular Risks. Pharmaceuticals, 2010, 3, 2146-2162.	1.7	157
336	Prostaglandin Endoperoxide Synthases. , 2010, , 35-63.		4
337	Selective Visualization of Cyclooxygenase-2 in Inflammation and Cancer by Targeted Fluorescent Imaging Agents. Cancer Research, 2010, 70, 3618-3627.	0.4	154
338	Coxibs interfere with the action of aspirin by binding tightly to one monomer of cyclooxygenase-1. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 28-33.	3.3	159
339	Molecular basis of cyclooxygenase enzymes (COXs) selective inhibition. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 5411-5416.	3.3	187

#	ARTICLE	IF	CITATIONS
340	Selective COX-1 Inhibition: A Therapeutic Target to be Reconsidered. <i>Current Medicinal Chemistry</i> , 2010, 17, 3769-3805.	1.2	130
341	Progress in COX-2 Inhibitors: A Journey So Far. <i>Current Medicinal Chemistry</i> , 2010, 17, 1563-1593.	1.2	122
342	Vane's discovery of the mechanism of action of aspirin changed our understanding of its clinical pharmacology. <i>Pharmacological Reports</i> , 2010, 62, 518-525.	1.5	103
343	Mono-, Di-, and Triaryl Substituted Tetrahydropyrans as Cyclooxygenase-2 and Tumor Growth Inhibitors. Synthesis and Biological Evaluation. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 3707-3717.	2.9	45
344	Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Progress in Small Molecule Drug Development. <i>Pharmaceuticals</i> , 2010, 3, 1530-1549.	1.7	80
345	Prostaglandin H synthase: Resolved and unresolved mechanistic issues. <i>Archives of Biochemistry and Biophysics</i> , 2010, 493, 103-124.	1.4	84
346	The N-terminus of COX-1 and its effect on cyclooxygenase-1 catalytic activity. <i>Journal of Genetics and Genomics</i> , 2010, 37, 117-123.	1.7	7
347	Principles of Immunopharmacology. , 2011, , .		14
348	Two-Level Adsorption of Ibuprofen on C ₆₀ Fullerene for Transdermal Delivery: Classical Molecular Dynamics and Density Functional Theory Computations. <i>Journal of Physical Chemistry C</i> , 2011, 115, 24501-24511.	1.5	24
349	Ethanesulfohydroxamic Acid Ester Prodrugs of Nonsteroidal Anti-inflammatory Drugs (NSAIDs): Synthesis, Nitric oxide and Nitroxyl Release, Cyclooxygenase Inhibition, Anti-inflammatory, and Ulcerogenicity Index Studies. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 1356-1364.	2.9	64
350	Cyclooxygenase-2 in oncogenesis. <i>Clinica Chimica Acta</i> , 2011, 412, 671-687.	0.5	135
351	The structure of NS-398 bound to cyclooxygenase-2. <i>Journal of Structural Biology</i> , 2011, 176, 254-258.	1.3	27
353	Nonsteroidal anti-inflammatory drugs. , 0, , 548-562.		0
354	Eicosanoids in Prevention and Management of Diseases. <i>Current Molecular Medicine</i> , 2011, 11, 13-25.	0.6	19
356	THE CHEMICAL AND STRUCTURAL BASES OF HEME RECOGNITION: Binding Interactions of Heme with Proteins and Peptides. , 2011, , 161-196.		1
357	Synthesis and biological evaluation of loxoprofen derivatives. <i>Bioorganic and Medicinal Chemistry</i> , 2011, 19, 3299-3311.	1.4	14
358	Cyclooxygenase inhibitors: Scope of their use and development in cancer chemotherapy. <i>Medicinal Research Reviews</i> , 2011, 31, 161-201.	5.0	49
359	Structural comparisons of arachidonic acid-induced radicals formed by prostaglandin H synthase-1 and -2. <i>Journal of Inorganic Biochemistry</i> , 2011, 105, 366-374.	1.5	1

#	ARTICLE	IF	CITATIONS
360	Many Putative Endocrine Disruptors Inhibit Prostaglandin Synthesis. <i>Environmental Health Perspectives</i> , 2011, 119, 534-541.	2.8	85
361	Modification of Rat Model of Sciatica Induced by Lumbar Disc Herniation and the Anti-Inflammatory Effect of Osthole Given by Epidural Catheterization. <i>Pharmacology</i> , 2012, 90, 251-263.	0.9	12
362	Use of Non-steroidal Anti-inflammatory Drugs in Pregnancy: Impact on the Fetus and Newborn. <i>Current Drug Metabolism</i> , 2012, 13, 474-490.	0.7	203
363	Investigating Substrate Promiscuity in Cyclooxygenase-2. <i>Journal of Biological Chemistry</i> , 2012, 287, 24619-24630.	1.6	46
364	Dual role of cyclooxygenase-2 during tissue repair induced by low level laser therapy: An intriguing issue. <i>Journal of Cosmetic and Laser Therapy</i> , 2012, 87, 184-188.	0.3	5
365	Comparative Binding Effects of Aspirin and Anti-Inflammatory Cu Complex in the Active Site of LOX-1. <i>Journal of Chemical Information and Modeling</i> , 2012, 52, 3293-3301.	2.5	10
366	Inactivation of Ovine Cyclooxygenase-1 by Bromoaspirin and Aspirin: A Quantum Chemistry Description. <i>Journal of Physical Chemistry B</i> , 2012, 116, 3270-3279.	1.2	20
367	Nitric Oxide Release Is Not Required to Decrease the Ulcerogenic Profile of Nonsteroidal Anti-inflammatory Drugs. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 688-696.	2.9	15
368	COX-2 as a molecular target of colon cancer chemoprevention: Promise and reality. <i>Biomedicine and Aging Pathology</i> , 2012, 2, 67-72.	0.8	4
369	Indole based cyclooxygenase inhibitors: Synthesis, biological evaluation, docking and NMR screening. <i>European Journal of Medicinal Chemistry</i> , 2012, 54, 823-833.	2.6	36
370	Synthesis and Biological Evaluation of Derivatives of 2-{2-Fluoro-4-[(2-oxocyclopentyl)methyl]phenyl}propanoic Acid: Nonsteroidal Anti-Inflammatory Drugs with Low Gastric Ulcerogenic Activity. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 5143-5150.	2.9	23
371	Aspirin: Pharmacology and Clinical Applications. <i>Thrombosis</i> , 2012, 2012, 1-15.	1.4	48
372	Thrombosis and Aspirin: Clinical Aspect, Aspirin in Cardiology, Aspirin in Neurology, and Pharmacology of Aspirin. <i>Thrombosis</i> , 2012, 2012, 1-1.	1.4	3
373	The Role of COX-2 Inhibitors on Experimental Colitis. , 0, , .		0
374	Conformational and thermodynamic analysis of the COXIB scaffold using quantum chemical calculations. <i>International Journal of Quantum Chemistry</i> , 2012, 112, 922-936.	1.0	1
375	Inflammation and Cancer: Chemical Approaches to Mechanisms, Imaging, and Treatment. <i>Journal of Organic Chemistry</i> , 2012, 77, 5224-5238.	1.7	47
376	Diarylheterocycle Core Ring Features Effect in Selective COX-1 Inhibition. <i>ChemMedChem</i> , 2012, 7, 629-641.	1.6	32
377	Design, synthesis, computational and biological evaluation of some new hydrazino derivatives of DHA and pyranopyrazoles. <i>European Journal of Medicinal Chemistry</i> , 2012, 50, 81-89.	2.6	52

#	ARTICLE	IF	CITATIONS
378	Synthesis and biological evaluation of isoxazolo[4,5-d]pyridazin-4-(5H)-one analogues as potent anti-inflammatory agents. <i>Bioorganic and Medicinal Chemistry</i> , 2012, 20, 2912-2922.	1.4	41
379	Seasonal variation in the cyclooxygenase inhibitory activities of four South African medicinal bulbs. <i>South African Journal of Botany</i> , 2012, 78, 246-251.	1.2	7
380	Rofecoxib Analogues Possessing a Nitric Oxide Donor Sulfohydroxamic Acid (SO ₂ NHOH) Cyclooxygenase-2 Pharmacophore: Synthesis, Molecular Modeling, and Biological Evaluation as Anti-inflammatory Agents. <i>ChemMedChem</i> , 2012, 7, 62-67.	1.6	24
381	4-Fluorophenylhydrazones as potential COX-2 inhibitors: a novel, efficient, one pot solid phase synthesis, docking study and pharmacological evaluation. <i>Medicinal Chemistry Research</i> , 2013, 22, 5890-5900.	1.1	11
383	Drug/drug interaction of common NSAIDs with antiplatelet effect of aspirin in human platelets. <i>European Journal of Pharmacology</i> , 2013, 721, 215-224.	1.7	69
384	Fluorescence Discrimination of Cancer from Inflammation by Molecular Response to COX-2 Enzymes. <i>Journal of the American Chemical Society</i> , 2013, 135, 17469-17475.	6.6	143
385	Hybrid fluorescent conjugates of COX-2 inhibitors: Search for a COX-2 isozyme imaging cancer biomarker. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 163-168.	1.0	37
386	Synthesis of three 18F-labelled cyclooxygenase-2 (COX-2) inhibitors based on a pyrimidine scaffold. <i>Organic and Biomolecular Chemistry</i> , 2013, 11, 8052.	1.5	28
387	Nanohybridization of Low-Dimensional Nanomaterials: Synthesis, Classification, and Application. <i>Critical Reviews in Solid State and Materials Sciences</i> , 2013, 38, 1-56.	6.8	20
388	Valdecoxib: the rise and fall of a COX-2 inhibitor. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 1077-1086.	0.9	39
389	The 2-Trifluoromethyl Analogue of Indomethacin Is a Potent and Selective COX-2 Inhibitor. <i>ACS Medicinal Chemistry Letters</i> , 2013, 4, 486-490.	1.3	60
390	Design, Synthesis, and Structure-Activity Relationship Studies of Fluorescent Inhibitors of Cyclooxygenase-2 as Targeted Optical Imaging Agents. <i>Bioconjugate Chemistry</i> , 2013, 24, 712-723.	1.8	70
391	Synthesis and in-silico studies of some diaryltriazole derivatives as potential cyclooxygenase inhibitors. <i>Archives of Pharmacal Research</i> , 2013, 36, 553-563.	2.7	4
393	Synthesis, Pharmacological Characterization, and Docking Analysis of a Novel Family of Diarylisoxazoles as Highly Selective Cyclooxygenase-1 (COX-1) Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 4277-4299.	2.9	88
394	Structural Determinants of Drug Partitioning in n-Hexadecane/Water System. <i>Journal of Chemical Information and Modeling</i> , 2013, 53, 1424-1435.	2.5	14
395	Structural Determinants of Drug Partitioning in Surrogates of Phosphatidylcholine Bilayer Strata. <i>Molecular Pharmaceutics</i> , 2013, 10, 3684-3696.	2.3	12
396	Historical Lessons in Translational Medicine. <i>Circulation Research</i> , 2013, 112, 174-194.	2.0	38
399	Inhibition of Endocannabinoid Metabolism by the Metabolites of Ibuprofen and Flurbiprofen. <i>PLoS ONE</i> , 2014, 9, e103589.	1.1	9

#	ARTICLE	IF	CITATIONS
400	Pharmacophore modeling for COX-1 and -2 inhibitors with LigandScout in comparison to Discovery Studio. <i>Future Medicinal Chemistry</i> , 2014, 6, 1869-1881.	1.1	43
401	Oxicams, a class of nonsteroidal anti-inflammatory drugs and beyond. <i>IUBMB Life</i> , 2014, 66, 803-811.	1.5	87
402	Fractals and self-organized criticality in anti-inflammatory drugs. <i>Physica A: Statistical Mechanics and Its Applications</i> , 2014, 415, 538-543.	1.2	9
403	New Functions of Old Drugs: Aureolic Acid Group of Anti-Cancer Antibiotics and Non-Steroidal Anti-Inflammatory Drugs. , 2014, , 3-55.		4
404	Fluorophore-Labeled Cyclooxygenase-2 Inhibitors for the Imaging of Cyclooxygenase-2 Overexpression in Cancer: Synthesis and Biological Studies. <i>ChemMedChem</i> , 2014, 9, 109-116.	1.6	36
405	Selective COX-1 inhibition as a target of theranostic novel diarylisoxazoles. <i>European Journal of Medicinal Chemistry</i> , 2014, 74, 606-618.	2.6	39
406	Oxicams Bind in a Novel Mode to the Cyclooxygenase Active Site via a Two-water-mediated H-bonding Network. <i>Journal of Biological Chemistry</i> , 2014, 289, 6799-6808.	1.6	90
407	Synthesis, molecular modeling and anti-inflammatory screening of novel fluorinated quinoline incorporated benzimidazole derivatives using the Pfitzinger reaction. <i>Journal of Fluorine Chemistry</i> , 2014, 161, 87-94.	0.9	30
408	Structure-Based Prediction of Drug Distribution Across the Headgroup and Core Strata of a Phospholipid Bilayer Using Surrogate Phases. <i>Molecular Pharmaceutics</i> , 2014, 11, 3577-3595.	2.3	11
409	Cyclooxygenase-2 in epilepsy. <i>Epilepsia</i> , 2014, 55, 17-25.	2.6	146
410	Propyphenazone-Based Analogues as Prodrugs and Selective Cyclooxygenase-2 Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2014, 5, 983-988.	1.3	12
411	Design, synthesis and structure-activity relationship studies of novel and diverse cyclooxygenase-2 inhibitors as anti-inflammatory drugs. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2014, 29, 846-867.	2.5	7
412	Substrate Specificity, Inhibitor Selectivity and Structure-Function Relationships of Aldo-Keto Reductase 1B15: A Novel Human Retinaldehyde Reductase. <i>PLoS ONE</i> , 2015, 10, e0134506.	1.1	17
413	Environmental Factors in the Relapse and Recurrence of Inflammatory Bowel Disease: A Review of the Literature. <i>Digestive Diseases and Sciences</i> , 2015, 60, 1396-1405.	1.1	48
414	Insertion and self-diffusion of a monotopic protein, the Aquifex aeolicus sulfide quinone reductase, in supported lipid bilayers. <i>European Physical Journal E</i> , 2015, 38, 110.	0.7	8
415	Tumor cell survival pathways activated by photodynamic therapy: a molecular basis for pharmacological inhibition strategies. <i>Cancer and Metastasis Reviews</i> , 2015, 34, 643-690.	2.7	191
416	Bacterial and algal orthologs of prostaglandin H2 synthase: novel insights into the evolution of an integral membrane protein. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2015, 1848, 83-94.	1.4	4
417	Flavonoids Inhibit COX-1 and COX-2 Enzymes and Cytokine/Chemokine Production in Human Whole Blood. <i>Inflammation</i> , 2015, 38, 858-870.	1.7	92

#	ARTICLE	IF	CITATIONS
418	Quantitative structure–activity relationship based modeling of substituted indole Schiff bases as inhibitor of COX-2. <i>Journal of Saudi Chemical Society</i> , 2016, 20, S457-S462.	2.4	5
419	Effects of Common Pesticides on Prostaglandin D2 (PGD2) Inhibition in SC5 Mouse Sertoli Cells, Evidence of Binding at the COX-2 Active Site, and Implications for Endocrine Disruption. <i>Environmental Health Perspectives</i> , 2016, 124, 452-459.	2.8	32
420	Aspirin Intolerance: Experimental Models for Bed-to-Bench. <i>Current Drug Targets</i> , 2016, 17, 1963-1970.	1.0	3
421	Paulistinea–The Functional Duality of a Wasp Venom Peptide Toxin. <i>Toxins</i> , 2016, 8, 61.	1.5	5
422	Synthesis of Novel Substituted Thiourea and Benzimidazole Derivatives Containing a Pyrazolone Ring as Anti–Inflammatory Agents. <i>Chemical Biology and Drug Design</i> , 2016, 87, 784-793.	1.5	23
423	A <i>Double Whammy</i>: Targeting Both Fatty Acid Amide Hydrolase (FAAH) and Cyclooxygenase (COX) To Treat Pain and Inflammation. <i>ChemMedChem</i> , 2016, 11, 1242-1251.	1.6	16
424	Synthesis and Biological Evaluation of New Phthalazinone Derivatives as Anti–Inflammatory and Anti–Proliferative Agents. <i>Archiv Der Pharmazie</i> , 2016, 349, 150-159.	2.1	10
425	Fatty Acid Binding to the Allosteric Subunit of Cyclooxygenase-2 Relieves a Tonic Inhibition of the Catalytic Subunit. <i>Journal of Biological Chemistry</i> , 2016, 291, 25641-25655.	1.6	25
426	Carboxylic Acid Nonsteroidal Anti-Inflammatory Drugs (NSAIDs). , 0, , 221-236.		11
427	Substrate-selective Inhibition of Cyclooxygenase-2 by Fenamic Acid Derivatives Is Dependent on Peroxide Tone. <i>Journal of Biological Chemistry</i> , 2016, 291, 15069-15081.	1.6	129
428	Discovery of a potent cyclooxygenase-2 inhibitor, S4, through docking-based pharmacophore screening, in vivo and in vitro estimations. <i>Molecular BioSystems</i> , 2016, 12, 2541-2551.	2.9	3
429	Conservative Secondary Shell Substitution In Cyclooxygenase-2 Reduces Inhibition by Indomethacin Amides and Esters via Altered Enzyme Dynamics. <i>Biochemistry</i> , 2016, 55, 348-359.	1.2	6
430	A quinazoline-based HDAC inhibitor affects gene expression pathways involved in cholesterol biosynthesis and mevalonate in prostate cancer cells. <i>Molecular BioSystems</i> , 2016, 12, 839-849.	2.9	7
431	The drug–target residence time model: a 10-year retrospective. <i>Nature Reviews Drug Discovery</i> , 2016, 15, 87-95.	21.5	540
432	Discovery of novel hybrids of diaryl-1,2,4-triazoles and caffeic acid as dual inhibitors of cyclooxygenase-2 and 5-lipoxygenase for cancer therapy. <i>European Journal of Medicinal Chemistry</i> , 2016, 108, 89-103.	2.6	77
433	Evolution to low-dose NSAID therapy. <i>Pain Management</i> , 2016, 6, 175-189.	0.7	8
434	Crystal Structure of Aspirin-Acetylated Human Cyclooxygenase-2: Insight into the Formation of Products with Reversed Stereochemistry. <i>Biochemistry</i> , 2016, 55, 1226-1238.	1.2	153
435	Deciphering the mechanism behind the varied binding activities of COXIBs through Molecular Dynamic Simulations, MM-PBSA binding energy calculations and per-residue energy decomposition studies. <i>Journal of Biomolecular Structure and Dynamics</i> , 2017, 35, 868-882.	2.0	41

#	ARTICLE	IF	CITATIONS
436	Biological activity evaluation and molecular docking study of chromone derivatives as cyclooxygenase-2 inhibitors. <i>Medicinal Chemistry Research</i> , 2017, 26, 662-671.	1.1	11
437	Nonsteroidal Anti-inflammatory Drug Use in Horses. <i>Veterinary Clinics of North America Equine Practice</i> , 2017, 33, 1-15.	0.3	32
438	Synthesis and molecular docking of new imidazoquinazolinones as analgesic agents and selective COX-2 inhibitors. <i>Future Medicinal Chemistry</i> , 2017, 9, 553-578.	1.1	17
439	In situ click chemistry generation of cyclooxygenase-2 inhibitors. <i>Nature Communications</i> , 2017, 8, 1.	5.8	10,736
441	Effects of <i>Tribulus terrestris</i> on monosodium iodoacetate-induced osteoarthritis pain in rats. <i>Molecular Medicine Reports</i> , 2017, 16, 5303-5311.	1.1	11
442	Structural basis for selective inhibition of Cyclooxygenase-1 (COX-1) by diarylisoxazoles mofezolac and 3-(5-chlorofuran-2-yl)-5-methyl-4-phenylisoxazole (P6). <i>European Journal of Medicinal Chemistry</i> , 2017, 138, 661-668.	2.6	63
443	COX Inhibition Profile and Molecular Docking Studies of Some 2-(Trimethoxyphenyl)-Thiazoles. <i>Molecules</i> , 2017, 22, 1507.	1.7	42
444	Variability of the drug response to nonsteroidal anti-inflammatory drugs according to cyclooxygenase-2 genetic polymorphism. <i>Drug Design, Development and Therapy</i> , 2017, Volume 11, 2727-2736.	2.0	11
445	Interplay between adenosine receptor antagonist and cyclooxygenase inhibitor in haloperidol-induced extrapyramidal effects in mice. <i>Metabolic Brain Disease</i> , 2018, 33, 1045-1051.	1.4	1
446	Molecular modelling insights into a physiologically favourable approach to eicosanoid biosynthesis inhibition through novel thieno[2,3- <i>b</i>]pyridine derivatives. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2018, 33, 755-767.	2.5	19
447	2-(4-Methylsulfonylphenyl)pyrimidines as Prospective Radioligands for Imaging Cyclooxygenase-2 with PET: Synthesis, Triage, and Radiolabeling. <i>Molecules</i> , 2018, 23, 2850.	1.7	16
448	Profiling the interaction of 1-phenylbenzimidazoles to cyclooxygenases. <i>Journal of Molecular Recognition</i> , 2019, 32, e2801.	1.1	1
449	Experimental and theoretical investigations of cyclometalated ruthenium(ii) complex containing CCC-pincer and anti-inflammatory drugs as ligands: synthesis, characterization, inhibition of cyclooxygenase and in vitro cytotoxicity activities in various cancer cell lines. <i>Dalton Transactions</i> , 2019, 48, 728-740.	1.6	24
450	Fluorescent indomethacin-dansyl conjugates utilize the membrane-binding domain of cyclooxygenase-2 to block the opening to the active site. <i>Journal of Biological Chemistry</i> , 2019, 294, 8690-8698.	1.6	21
451	Indomethacin from Anti-Inflammatory to Anticancer Agent. , 2019, , .		1
452	Synthesis and biological evaluation of pyridazinone derivatives as selective COX-2 inhibitors and potential anti-inflammatory agents. <i>European Journal of Medicinal Chemistry</i> , 2019, 171, 25-37.	2.6	47
453	C-phycocyanin: a natural product with radiosensitizing property for enhancement of colon cancer radiation therapy efficacy through inhibition of COX-2 expression. <i>Scientific Reports</i> , 2019, 9, 19161.	1.6	28
454	A novel single-chain enzyme complex with chain reaction properties rapidly producing thromboxane A ₂ and exhibiting powerful anti-bleeding functions. <i>Journal of Cellular and Molecular Medicine</i> , 2019, 23, 8343-8354.	1.6	7

#	ARTICLE	IF	CITATIONS
455	Known compounds and new lessons: structural and electronic basis of flavonoid-based bioactivities. <i>Journal of Biomolecular Structure and Dynamics</i> , 2020, 38, 1168-1184.	2.0	17
456	Ethyl benzoate bearing pyrrolizine/indolizine moieties: Design, synthesis and biological evaluation of anti-inflammatory and cytotoxic activities. <i>Bioorganic Chemistry</i> , 2020, 94, 103371.	2.0	20
457	Ligand- <i>Receptor</i> Binding Kinetics in Drug Design. <i>Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry</i> , 2020, 14, 228-240.	0.2	3
458	Synthesis, 3D-QSAR, and Molecular Modeling Studies of Triazole Bearing Compounds as a Promising Scaffold for Cyclooxygenase-2 Inhibition. <i>Pharmaceutics</i> , 2020, 13, 370.	1.7	5
459	Identification of Active Compounds From Yi Nationality Herbal Formula Wosi Influencing COX-2 and VCAM-1 Signaling. <i>Frontiers in Pharmacology</i> , 2020, 11, 568585.	1.6	5
460	In silico characterisation of olive phenolic compounds as potential cyclooxygenase modulators. Part 1. <i>Journal of Molecular Graphics and Modelling</i> , 2020, 101, 107719.	1.3	3
461	In silico characterisation of olive phenolic compounds as potential cyclooxygenase modulators. Part 2. <i>Journal of Molecular Graphics and Modelling</i> , 2020, 101, 107743.	1.3	1
462	Synthesis of novel 3,5,6-trisubstituted 2-pyridone derivatives and evaluation for their anti-inflammatory activity. <i>Bioorganic and Medicinal Chemistry</i> , 2020, 28, 115549.	1.4	13
463	CYP2J2 Molecular Recognition: A New Axis for Therapeutic Design. , 2020, 215, 107601.		32
464	Synthesis of novel <i>N</i> -substitutedphenyl- <i>oxo</i> - <i>phenyl</i> pyridazine derivatives as cyclooxygenase-2 inhibitors. <i>Drug Development Research</i> , 2020, 81, 573-584.	1.4	9
465	Structural and Chemical Biology of the Interaction of Cyclooxygenase with Substrates and Non-Steroidal Anti-Inflammatory Drugs. <i>Chemical Reviews</i> , 2020, 120, 7592-7641.	23.0	64
466	Design, synthesis and biological evaluation of novel pyrazole sulfonamide derivatives as dual COX-2/5-LOX inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2020, 189, 112066.	2.6	51
467	Discovery of Novel Pyridazine-Based Cyclooxygenase-2 Inhibitors with a Promising Gastric Safety Profile. <i>Molecules</i> , 2020, 25, 2002.	1.7	17
468	Paracetamol - An old drug with new mechanisms of action. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2021, 48, 3-19.	0.9	78
469	Design, Synthesis of Analgesics and Anticancer of Some New Derivatives of Benzimidazole. <i>International Journal of Organic Chemistry</i> , 2021, 11, 144-169.	0.3	4
470	The Protective Role of <i>Urtica dioica</i> Seed Extract Against Azoxymethane-Induced Colon Carcinogenesis in Rats. <i>Nutrition and Cancer</i> , 2022, 74, 306-319.	0.9	6
471	Discovery of Bis-sydnone styryl ketone as a selective cyclooxygenase-2 inhibitor. <i>Future Journal of Pharmaceutical Sciences</i> , 2021, 7, .	1.1	0
473	Pharmacophore model, docking, QSAR, and molecular dynamics simulation studies of substituted cyclic imides and herbal medicines as COX-2 inhibitors. <i>Heliyon</i> , 2021, 7, e06605.	1.4	19

#	ARTICLE	IF	CITATIONS
474	Toward Multitasking Pharmacological COX-Targeting Agents: Non-Steroidal Anti-Inflammatory Prodrugs with Antiproliferative Effects. <i>Molecules</i> , 2021, 26, 3940.	1.7	7
475	Roles of Eicosanoids in Regulating Inflammation and Neutrophil Migration as an Innate Host Response to Bacterial Infections. <i>Infection and Immunity</i> , 2021, 89, e0009521.	1.0	35
476	Chance Favors the Perplexed Mind: The Critical Role of Mechanistic Biochemistry in Drug Discovery. <i>Biochemistry</i> , 2021, 60, 2275-2284.	1.2	2
477	Design and Synthesis of Novel Ibuprofen Derivatives as Selective COX-2 Inhibitors and Potential Anti-Inflammatory Agents: Evaluation of PGE ₂ , TNF- α , IL-6 and Histopathological Study. <i>Medicinal Chemistry</i> , 2022, 18, 427-443.	0.7	4
478	Synthetically-tailored and nature-derived dual COX-2/5-LOX inhibitors: Structural aspects and SAR. <i>European Journal of Medicinal Chemistry</i> , 2021, 225, 113804.	2.6	28
479	Cyclooxygenases. , 0, , 65-88.		2
480	Analysis of Cyclooxygenase-Substrate Interactions Using Stereospecificallylabeled Arachidonic Acids. <i>Advances in Experimental Medicine and Biology</i> , 2002, 507, 49-53.	0.8	1
481	Three-Dimensional Crystallization of Membrane Proteins. <i>Methods in Molecular Biology</i> , 2007, 363, 191-223.	0.4	3
482	COX-2 Signaling in the Tumor Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1277, 87-104.	0.8	17
483	The discovery of COX-2. , 2004, , 1-13.		3
484	Fatty-Acid Substrate Interactions with Cyclo-oxygenases. , 2000, , 53-64.		4
485	Structure, Function and Inhibition of Cyclo-oxygenases. , 2000, , 65-83.		3
486	Anti-inflammatory and immunosuppressant drugs. , 2012, , 318-335.		3
487	Nonsteroidal Anti-inflammatory Drugs. , 2009, , 833-861.		3
488	The Peroxidase and Cyclooxygenase Activity of Prostaglandin H Synthase. 2-Oxoglutarate-Dependent Oxygenases, 2015, , 245-271.	0.8	3
489	Cyclooxygenase-2 in the Kidney. <i>Journal of the American Society of Nephrology: JASN</i> , 2000, 11, 2387-2394.	3.0	99
490	Radiotracers for Molecular Imaging of Cyclooxygenase-2 (COX-2) Enzyme. <i>Current Medicinal Chemistry</i> , 2013, 20, 4350-4369.	1.2	36
491	Role of the prostaglandins in labour and prostaglandin receptor inhibitors in the prevention of preterm labour. <i>Frontiers in Bioscience - Landmark</i> , 2007, 12, 1329.	3.0	105

#	ARTICLE	IF	CITATIONS
492	Virtual screening for potential COX-inhibiting constituents from <i>Mimosa pudica</i> . <i>Journal of Applied Pharmaceutical Science</i> , 0, , 071-075.	0.7	5
493	Nichtsaure antipyretische Analgetika. , 2001, , 387-394.		0
497	Halten die COX-2-Hemmer was sie versprechen?. , 2004, , 25-30.		0
499	Prostaglandin Endoperoxide Synthases: Structure, Function, and Synthesis of Novel Lipid Signaling Molecules. , 2010, , 114-136.		2
502	Clinical pharmacology of non-steroidal anti-inflammatory drugs: novel acquisitions. , 1999, , 135-139.		0
503	Comparison of Prostaglandin H Synthase-1 and -2 Structural Stabilities. <i>Advances in Experimental Medicine and Biology</i> , 1999, 469, 115-118.	0.8	0
504	Antiplatelet Effect of a Pulaimab [Anti-GPIIb/IIIa F(ab)2 Injection] Evaluated by a Population Pharmacokinetic-pharmacodynamic Model. <i>Current Drug Metabolism</i> , 2020, 20, 1060-1072.	0.7	0
507	The Fall of Titans: The Need to Reassess COX-2 Inhibitors. <i>McGill Journal of Medicine</i> , 2005, 8, .	0.1	0
508	A Case of Intranasal Meningocele. <i>McGill Journal of Medicine</i> , 2006, 9, .	0.1	3
509	Fish macrophages express a cyclo-oxygenase-2 homologue after activation. <i>Biochemical Journal</i> , 1999, 340 (Pt 1), 153-9.	1.7	10
510	A case of intranasal meningocele. <i>McGill Journal of Medicine</i> , 2006, 9, 31-3.	0.1	4
511	Design, synthesis and in vivo evaluation of 1,4-dioxo-2-butenyl aryl amine derivatives as a promising anti-inflammatory drug prototype. <i>Bioorganic Chemistry</i> , 2022, 124, 105754.	2.0	3
512	An Overview of Novel Bioactive Compounds with Potent Anti-Inflammatory Activity <i>via</i> Dual COX-2 and 5-LOX Enzyme Inhibition. <i>Current Bioactive Compounds</i> , 2022, 18, .	0.2	2
513	Cyclooxygenase-2 Inhibitor Treatment of Older Osteoarthritis Patients. <i>Comprehensive Therapy</i> , 2003, 29, 215-223.	0.2	0
517	Anti-inflammatory activity of pyridazinones: A review. <i>Archiv Der Pharmazie</i> , 2022, 355, e2200067.	2.1	6
520	Design, Synthesis and Biological Evaluation of Novel N-Alkyl-4-Methyl-2,2-Dioxo-1H-2H-6,1-Benzothiazine-3-Carboxamides as Promising Analgesics. <i>Medicinal Chemistry</i> , 2023, 19, 174-192.	0.7	1
521	Design, Synthesis and Bioevaluation of Highly Functionalized 1,2,3-Triazole-Guanidine Conjugates as Anti-Inflammatory and Antioxidant Agents. <i>Polycyclic Aromatic Compounds</i> , 0, , 1-15.	1.4	1
522	Analysis of Sex-Specific Prostanoid Production Using a Mouse Model of Selective Cyclooxygenase-2 Inhibition. <i>Biomarker Insights</i> , 2022, 17, 117727192211421.	1.0	0

#	ARTICLE	IF	CITATIONS
523	New NSAID Conjugates as Potent and Selective COX-2 Inhibitors: Synthesis, Molecular Modeling and Biological Investigation. <i>Molecules</i> , 2023, 28, 1945.	1.7	6
527	Cyclooxygenase. , 2024, , 431-447.		0